The decision centers on whether expert testimony regarding the potential connection between Tylenol use during pregnancy and the development of autism or ADHD meets the necessary threshold for court presentation. While the appeals court emphasized that this ruling does not confirm a causal link or establish liability for manufacturers, it serves as a critical procedural victory for parents seeking accountability.

Ruth Rizkalla, a partner at The Carlson Law Firm and member of the plaintiffs' leadership committee, noted that the appellate court’s move confirms that the families' experts possess a sound basis for their testimony. The cases now return to the district court level for further proceedings. For families to qualify for a case review, they must demonstrate that acetaminophen was used for an extended duration during pregnancy and that the child subsequently received a diagnosis of ADHD or autism spectrum disorder. The firm maintains that eligibility remains dependent on individual medical records and applicable filing deadlines.